Zymeworks discusses ADC ecosystem expertise
CMO Sabeen Mekan spoke with C&EN about ADC development and manufacturing challenges.
See the latest news and media coverage for Zymeworks. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing novel medicines
zymeworks.comLast updated
In short: Zymeworks reported positive clinical data, secured new drug approvals, and entered into an acquisition to expand its lung disease pipeline.
CMO Sabeen Mekan spoke with C&EN about ADC development and manufacturing challenges.
Leadership representatives will discuss company strategy, key business priorities, and the organization's diversified portfolio during these events.
The organization has released its press release and detailed financial results for the specified quarter.
The biotech firm seeks an Associate Director and Senior Program Manager in Dublin to lead cross-functional clinical development teams.
August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190...
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually...
Shares of Theravance Biopharma were sliding in premarket trading Monday after larger biotech...
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal...
Track Zymeworks and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zymeworks and other trending companies.